We applied a phase 2 clinical trial using reactor-based BNCT and simultaneous administration of bevacizumab for recurrent malignant gliomas with poor prognosis. ２０cases were set at the initial protocol, however only 4 cases were enrolled with this clinical trial. The reasons of shortage of the subjects in this clinical trials might be ascribed to unstable operation of Kyoto University Research Reactor and simultaneously started phase 2 accelerator-based BNCT clinical trial for recurrent malignant gliomas.
3 cases were dead due to tumor progression during the observation period and 1 case is still alive 19 months after BNCT. All cases showed the prolonged survival in comparison with historical control. No case showed brain radiation necrosis. We will not extend the period of case entry because all BNCT will be performed using accelerator very soon.